MarketWatch10h
Dr. Reddy's Laboratories outperforms competitors on strong trading day
Dr. Reddy's Laboratories Ltd. 500124 shares advanced 2.39% to 1,303.00 Indian rupees Wednesday, on what proved to be an ...
Dr. Reddy’s Labs Releases Unaudited Financial Results
Dr Reddy’s Laboratories (RDY) has released an update. Dr. Reddy’s Laboratories has released its unaudited financial results for the ...
Neutral Dr Reddys Laboratories; target of Rs 1390: Motilal Oswal
Motilal Oswal recommended Neutral rating on Dr Reddys Laboratories with a target price of Rs 1390 in its research report ...
Dr. Reddy's Laboratories rises Tuesday, still underperforms market
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...
Dr Reddy’s Laboratories (RDY) Gets a Buy from Barclays
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), ...
ndtvprofit10h
Dr Reddy's Aims To Consistently Deliver Double-Digit Sales Growth, Ebitda Margin Of 25%
Dr Reddy's expects overall sales to grow in double digits, with branded business in India and emerging markets growing in ...
cnbctv1817h
Dr. Reddy's analysts remain cautious citing lack of near-term catalysts post Q2
Out of the 40 analysts that track Dr. Reddy's, 13 of them have a 'Buy' recommendation, while 16 of them have a 'Sell' call.
Reduce Dr. Reddy's Laboratories; target of Rs 1335 Prabhudas Lilladher
Dr. Reddy’s (DRRD) Q2FY25 EBITDA was largely in line with our estimate. The base business margins and US sales ex of ...
ndtvprofit13h
Dr Reddy's Share Price Rises As Analysts Upgrade Rating, Hike Target Price
Systematix upgraded the stock rating to 'hold' and hiked target price to Rs 1,414 apiece, while Dolat Capital upgraded rating ...
Business Insider16h
Dr. Reddy’s Reports Strong Q2FY25 Results and Strategic Expansions
Dr. Reddy’s Laboratories Ltd ( (RDY)) has released its Q2 earnings. Here is a breakdown of the information Dr. Reddy’s Laboratories Ltd presented to its investors. Dr. Reddy’s ...